Darbepoetin alpha for the treatment of anaemia in low-intermediate risk myelodysplastic syndromes

Pellegrino Musto, Francesco Lanza, Enrico Balleari, Alberto Grossi, Antonietta Falcone, Grazia Sanpaolo, Carlo Bodenizza, Potito Rosario Scalzulli, Antonio La Sala, Diana Campioni, Riccardo Ghio, Nicola Cascavilia, Angelo Michele Carella

Research output: Contribution to journalArticle

Abstract

Thirty-seven anaemic subjects with low-to-intermediate risk myelodysplastic syndrome (MDS) received the highly glycosylated, long-acting erythropoiesis-stimulating molecule darbepoetin-alpha (DPO) at the single, weekly dose of 150 μg s.c. for at least 12 weeks. Fifteen patients (40-5%) achieved an erythroid response (13 major and two minor improvements, respectively, according to International Working Group criteria). Such results are currently maintained after 7-22 months in 13 of the responders, one of whom required iron substitutive therapy during the treatment. One patient relapsed after 4 months. Another responder died after 5 months because of causes unrelated to the treatment. No relevant side-effects were recorded. At multivariate analysis, significant predictive factors of response were baseline serum levels of endogenous erythropoietin

Original languageEnglish
Pages (from-to)204-209
Number of pages6
JournalBritish Journal of Haematology
Volume128
Issue number2
DOIs
Publication statusPublished - Jan 2005

Fingerprint

Myelodysplastic Syndromes
Anemia
Erythropoiesis
Erythropoietin
Therapeutics
Multivariate Analysis
Iron
Serum
Darbepoetin alfa

Keywords

  • Anaemia
  • Darbepoetin
  • Erythropoietin
  • Myelodysplastic syndromes
  • Transfusion

ASJC Scopus subject areas

  • Hematology

Cite this

Darbepoetin alpha for the treatment of anaemia in low-intermediate risk myelodysplastic syndromes. / Musto, Pellegrino; Lanza, Francesco; Balleari, Enrico; Grossi, Alberto; Falcone, Antonietta; Sanpaolo, Grazia; Bodenizza, Carlo; Scalzulli, Potito Rosario; La Sala, Antonio; Campioni, Diana; Ghio, Riccardo; Cascavilia, Nicola; Carella, Angelo Michele.

In: British Journal of Haematology, Vol. 128, No. 2, 01.2005, p. 204-209.

Research output: Contribution to journalArticle

Musto, Pellegrino ; Lanza, Francesco ; Balleari, Enrico ; Grossi, Alberto ; Falcone, Antonietta ; Sanpaolo, Grazia ; Bodenizza, Carlo ; Scalzulli, Potito Rosario ; La Sala, Antonio ; Campioni, Diana ; Ghio, Riccardo ; Cascavilia, Nicola ; Carella, Angelo Michele. / Darbepoetin alpha for the treatment of anaemia in low-intermediate risk myelodysplastic syndromes. In: British Journal of Haematology. 2005 ; Vol. 128, No. 2. pp. 204-209.
@article{e8b08c4b2b2a4bbb9ac3d8d09e2ced55,
title = "Darbepoetin alpha for the treatment of anaemia in low-intermediate risk myelodysplastic syndromes",
abstract = "Thirty-seven anaemic subjects with low-to-intermediate risk myelodysplastic syndrome (MDS) received the highly glycosylated, long-acting erythropoiesis-stimulating molecule darbepoetin-alpha (DPO) at the single, weekly dose of 150 μg s.c. for at least 12 weeks. Fifteen patients (40-5{\%}) achieved an erythroid response (13 major and two minor improvements, respectively, according to International Working Group criteria). Such results are currently maintained after 7-22 months in 13 of the responders, one of whom required iron substitutive therapy during the treatment. One patient relapsed after 4 months. Another responder died after 5 months because of causes unrelated to the treatment. No relevant side-effects were recorded. At multivariate analysis, significant predictive factors of response were baseline serum levels of endogenous erythropoietin",
keywords = "Anaemia, Darbepoetin, Erythropoietin, Myelodysplastic syndromes, Transfusion",
author = "Pellegrino Musto and Francesco Lanza and Enrico Balleari and Alberto Grossi and Antonietta Falcone and Grazia Sanpaolo and Carlo Bodenizza and Scalzulli, {Potito Rosario} and {La Sala}, Antonio and Diana Campioni and Riccardo Ghio and Nicola Cascavilia and Carella, {Angelo Michele}",
year = "2005",
month = "1",
doi = "10.1111/j.1365-2141.2004.05288.x",
language = "English",
volume = "128",
pages = "204--209",
journal = "British Journal of Haematology",
issn = "0007-1048",
publisher = "John Wiley & Sons, Ltd (10.1111)",
number = "2",

}

TY - JOUR

T1 - Darbepoetin alpha for the treatment of anaemia in low-intermediate risk myelodysplastic syndromes

AU - Musto, Pellegrino

AU - Lanza, Francesco

AU - Balleari, Enrico

AU - Grossi, Alberto

AU - Falcone, Antonietta

AU - Sanpaolo, Grazia

AU - Bodenizza, Carlo

AU - Scalzulli, Potito Rosario

AU - La Sala, Antonio

AU - Campioni, Diana

AU - Ghio, Riccardo

AU - Cascavilia, Nicola

AU - Carella, Angelo Michele

PY - 2005/1

Y1 - 2005/1

N2 - Thirty-seven anaemic subjects with low-to-intermediate risk myelodysplastic syndrome (MDS) received the highly glycosylated, long-acting erythropoiesis-stimulating molecule darbepoetin-alpha (DPO) at the single, weekly dose of 150 μg s.c. for at least 12 weeks. Fifteen patients (40-5%) achieved an erythroid response (13 major and two minor improvements, respectively, according to International Working Group criteria). Such results are currently maintained after 7-22 months in 13 of the responders, one of whom required iron substitutive therapy during the treatment. One patient relapsed after 4 months. Another responder died after 5 months because of causes unrelated to the treatment. No relevant side-effects were recorded. At multivariate analysis, significant predictive factors of response were baseline serum levels of endogenous erythropoietin

AB - Thirty-seven anaemic subjects with low-to-intermediate risk myelodysplastic syndrome (MDS) received the highly glycosylated, long-acting erythropoiesis-stimulating molecule darbepoetin-alpha (DPO) at the single, weekly dose of 150 μg s.c. for at least 12 weeks. Fifteen patients (40-5%) achieved an erythroid response (13 major and two minor improvements, respectively, according to International Working Group criteria). Such results are currently maintained after 7-22 months in 13 of the responders, one of whom required iron substitutive therapy during the treatment. One patient relapsed after 4 months. Another responder died after 5 months because of causes unrelated to the treatment. No relevant side-effects were recorded. At multivariate analysis, significant predictive factors of response were baseline serum levels of endogenous erythropoietin

KW - Anaemia

KW - Darbepoetin

KW - Erythropoietin

KW - Myelodysplastic syndromes

KW - Transfusion

UR - http://www.scopus.com/inward/record.url?scp=19944432966&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=19944432966&partnerID=8YFLogxK

U2 - 10.1111/j.1365-2141.2004.05288.x

DO - 10.1111/j.1365-2141.2004.05288.x

M3 - Article

C2 - 15638854

AN - SCOPUS:19944432966

VL - 128

SP - 204

EP - 209

JO - British Journal of Haematology

JF - British Journal of Haematology

SN - 0007-1048

IS - 2

ER -